Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden)

Dietary phytoestrogen, serum enterolactone and risk of prostate cancer : the cancer prostate Sweden study (Sweden)

Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden. Orebro Univ Hosp, Dept Urol, Orebro, Sweden. Ctr Assessment Med Technol, Orebro, Sweden. Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland. Univ Helsinki, Inst Prevent Med Nutr & Canc, Folkhalsan Res Ctr, Helsinki, Finland. Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden.Springer,2006
printrdacarrier

OBJECTIVE: Based on evidence that phytoestrogens may protect against prostate cancer, we evaluated the associations between serum enterolactone concentration or dietary phytoestrogen intake and risk of prostate cancer. METHODS: In our Swedish population-based case-control study, questionnaire-data were available for 1,499 prostate cancer cases and 1,130 controls, with serum enterolactone levels in a sub-group of 209 cases and 214 controls. Unconditional logistic regression was performed to estimate multivariate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with risk of prostate cancer. RESULTS: High intake of food items rich in phytoestrogens was associated with a decreased risk of prostate cancer. The OR comparing the highest to the lowest quartile of intake was 0.74 (95% CI: 0.57-0.95; p-value for trend: 0.01). In contrast, we found no association between dietary intake of total or individual lignans or isoflavonoids and risk of prostate cancer. Intermediate serum levels of enterolactone were associated with a decreased risk of prostate cancer. The ORs comparing increasing quartiles of serum enterolactone concentration to the lowest quartile were, respectively, 0.28 (95% CI: 0.15-0.55), 0.63 (95% CI: 0.35-1.14) and 0.74 (95% CI: 0.41-1.32). CONCLUSIONS: Our results support the hypothesis that certain foods high in phytoestrogens are associated with a lower risk of prostate cancer.

Klint, ÅsaKarolinska Institutet (författare)
Chang, Ellen T. (författare)
Bellocco, RinoKarolinska Institutet (författare)
Johansson, Jan-ErikÖrebro universitet,Hälsoakademin(Swepub:oru)jkjn (författare)
Andersson, Swen-OlofÖrebro universitet,Hälsoakademin(Swepub:oru)sfan (författare)
Heinonen, Satu-Maarit (författare)
Adlercreutz, Herman (författare)
Adami, Hans-OlovKarolinska Institutet (författare)
Grönberg, HenrikKarolinska Institutet,Umeå universitet,Onkologi (författare)
Bälter Augustsson, KatarinaKarolinska institutet, Sweden(Swepub:mdh)kbr01 (författare)
Karolinska InstitutetHälsoakademin (creator_code:org_t)

Ingår i:Cancer Causes and ControlKarolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden. Orebro Univ Hosp, Dept Urol, Orebro, Sweden. Ctr Assessment Med Technol, Orebro, Sweden. Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland. Univ Helsinki, Inst Prevent Med Nutr & Canc, Folkhalsan Res Ctr, Helsinki, Finland. Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden. : Springer17:2, s. 169-1800957-52431573-7225

Av författaren/redakt...: Hedelin, Maria; Klint, Åsa; Chang, Ellen T.; Bellocco, Rino; Johansson, Jan-E ...; Andersson, Swen- ...; visa fler...; Heinonen, Satu-M ...; Adlercreutz, Her ...; Adami, Hans-Olov; Grönberg, Henrik; Bälter Augustsso ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Av lärosätet: Örebro universitet; Umeå universitet; Mälardalens universitet; Karolinska Institutet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.